Group sales increased by 6% at constant exchange rates to CHF 14.7 billion during the first three months of 2026, driven by continued high demand for pharmaceutical products and diagnostic solutions. Reported sales in Swiss francs fell 5% due to severe currency headwinds and the appreciation of the Swiss franc against major currencies, particularly the U.S. dollar. Core earnings per share figures are only reported semi-annually, but Roche maintained its full-year guidance expecting mid-single-digit group sales growth and high-single-digit core EPS growth at constant exchange rates. Primary performance drivers included top-selling innovative medicines like Xolair, Phesgo, Hemlibra, and Vabysmo, alongside steady expansion in core lab diagnostics.
Note: Roche Holdings's FY 2025 ended on December 31, 2025. Q1 FY 2026 ended on March 31, 2026.
In May 2026, Roche signed a definitive merger agreement to acquire PathAI, a leader in AI-powered pathology technology, for an upfront purchase price of USD 750 million plus up to USD 300 million in milestone payments. The transaction integrates PathAI's advanced Image Management System and AI analysis tools into Roche's existing Diagnostics division. This acquisition is designed to transform manual workflows into automated, AI-driven processes, enhancing Roche's competitive positioning in precision medicine, accelerating companion diagnostic discovery, and improving clinical trial workflows for its global biopharma services.
Below are key drivers of Roche Holdings's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Roche Holdings at the top of the page.
Roche Holdings operates a unique dual-engine business model that tightly integrates its global Pharmaceuticals and Diagnostics divisions to lead the field of precision medicine. The company leverages its massive clinical datasets to develop innovative targeted therapies for oncology, immunology, and ophthalmology, while simultaneously commercializing advanced laboratory systems, tissue pathology platforms, and digital diagnostic software solutions worldwide.
The Pharmaceuticals division acts as the primary source of enterprise value for Roche because its specialized portfolio of innovative biologic drugs yields exceptionally high gross margins and sustained recurring revenue streams across multiple therapeutic fields.
Roche maintains a dominant position in cancer treatment through complex monoclonal antibodies and bispecific formulations that require massive scientific expertise and long-term production scale. This technical complexity creates a steep barrier to entry for generic manufacturers and establishes an insulated, high-value clinical franchise.
By pairing its therapeutic pipeline with a world-class in-house Diagnostics infrastructure, Roche can develop proprietary testing kits concurrently with clinical trial programs. This combined footprint allows the company to secure early institutional adoption, lock in testing protocols at hospital labs, and protect product pricing tiers through demonstrable superior patient outcomes.
The healthcare industry is aggressively pivoting toward digital tools that automate workflow analytics and enhance diagnostic precision. Roche's strategic moves to fully integrate advanced artificial intelligence capabilities directly into pathology laboratories reflect an industry-wide trend toward using algorithmic data processing to scale clinical efficiency and discover novel biomarkers.
Major pharmaceutical developers are shifting capital allocations toward metabolic and obesity therapies to capture rapid market growth. Roche is focusing its clinical strategy around expanding trials for its oral GLP-1 receptor agonist and subcutaneous combinations, aiming to combine its traditional oncology and diagnostic strengths with high-velocity metabolic platforms.
